This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
rna viruses | 648 |
viral rna | 612 |
viral infection | 611 |
influenza virus | 603 |
viral replication | 561 |
viral load | 501 |
viral infections | 495 |
virus infection | 493 |
immune response | 446 |
host cell | 406 |
infected cells | 405 |
viral proteins | 389 |
respiratory tract | 338 |
virus replication | 338 |
gene expression | 334 |
acute respiratory | 323 |
viral genome | 320 |
herpes simplex | 309 |
rna virus | 287 |
simplex virus | 281 |
virus type | 265 |
immune responses | 259 |
viral particles | 258 |
immunodeficiency virus | 247 |
respiratory viruses | 238 |
epithelial cells | 237 |
respiratory syndrome | 237 |
type i | 234 |
nucleic acid | 234 |
immune system | 232 |
human immunodeficiency | 230 |
innate immune | 228 |
rna polymerase | 221 |
severe acute | 201 |
host cells | 200 |
viral genomes | 196 |
viral protein | 195 |
cell culture | 191 |
amino acid | 185 |
plasma membrane | 176 |
respiratory syncytial | 168 |
protein synthesis | 167 |
viral dna | 165 |
vaccinia virus | 164 |
syncytial virus | 160 |
antiviral activity | 159 |
dna viruses | 159 |
stranded rna | 154 |
rna interference | 152 |
cell surface | 151 |
host factors | 151 |
life cycle | 146 |
doc id | 145 |
cord uid | 145 |
viral gene | 143 |
translation initiation | 140 |
infectious diseases | 138 |
vesicular stomatitis | 137 |
capsid protein | 136 |
stomatitis virus | 133 |
may also | 131 |
silver nanoparticles | 125 |
enveloped viruses | 125 |
disease virus | 124 |
dengue virus | 123 |
binding protein | 121 |
bovine viral | 121 |
viral entry | 120 |
respiratory infections | 118 |
syndrome coronavirus | 118 |
genomic rna | 116 |
host immune | 116 |
virus infections | 116 |
mouth disease | 115 |
class i | 114 |
influenza viruses | 114 |
viral loads | 113 |
reverse transcription | 113 |
nucleic acids | 111 |
rna replication | 111 |
defective interfering | 110 |
virus particles | 110 |
rna recombination | 108 |
cell lines | 108 |
viral diseases | 106 |
protein kinase | 105 |
time pcr | 105 |
united states | 104 |
chain reaction | 104 |
viral pathogens | 104 |
common cold | 103 |
reverse transcriptase | 103 |
respiratory viral | 103 |
dependent rna | 102 |
lower respiratory | 102 |
polymerase chain | 101 |
upper respiratory | 99 |
viral diarrhea | 99 |
human rhinovirus | 98 |
antiviral therapy | 98 |
respiratory virus | 98 |
ebola virus | 97 |
mammalian cells | 96 |
fever virus | 96 |
diarrhea virus | 96 |
rna synthesis | 95 |
antiviral agents | 94 |
public health | 94 |
west nile | 93 |
structural proteins | 93 |
clinical trials | 93 |
target cells | 92 |
antiviral drugs | 92 |
strand rna | 91 |
viral pneumonia | 91 |
drug delivery | 90 |
acquired pneumonia | 90 |
i interferon | 89 |
infl uenza | 89 |
neutralizing antibodies | 89 |
membrane fusion | 87 |
cell death | 87 |
cell spread | 87 |
barr virus | 86 |
symptom onset | 86 |
viral respiratory | 85 |
nile virus | 84 |
viral mrnas | 84 |
endoplasmic reticulum | 83 |
viral pathogenesis | 83 |
drug resistance | 83 |
rna genome | 82 |
hiv infection | 81 |
innate immunity | 81 |
cell cycle | 80 |
many viruses | 78 |
cellular mrnas | 78 |
viral shedding | 77 |
host proteins | 77 |
viral mrna | 77 |
infected cell | 76 |
measles virus | 76 |
large number | 76 |
viral nucleic | 76 |
important role | 75 |
coronavirus disease | 73 |
infected patients | 73 |
viral life | 73 |
genome replication | 71 |
viral sequences | 71 |
novel coronavirus | 71 |
amino acids | 71 |
viruses may | 70 |
sindbis virus | 70 |
virus entry | 70 |
infected mice | 70 |
animal viruses | 70 |
cellular proteins | 70 |
nervous system | 69 |
viral species | 69 |
intensive care | 69 |
mutant spectrum | 69 |
extracellular vesicles | 69 |
respiratory disease | 69 |
viral disease | 68 |
dendritic cells | 68 |
iav infection | 67 |
mosaic virus | 67 |
respiratory infection | 67 |
cell membrane | 66 |
tract infections | 66 |
mhc class | 66 |
adaptive immune | 66 |
binding proteins | 65 |
infectious virus | 65 |
viral genomic | 65 |
viral envelope | 65 |
cells infected | 65 |
human cytomegalovirus | 64 |
binding site | 63 |
risk factors | 63 |
monoclonal antibodies | 63 |
replication cycle | 63 |
recent studies | 62 |
influenza infection | 62 |
rna binding | 62 |
rna pol | 62 |
swine fever | 62 |
capsid proteins | 62 |
viral genes | 61 |
streptococcus pneumoniae | 61 |
viral metagenomics | 61 |
high viral | 61 |
interfering particles | 60 |
cell line | 60 |
heart failure | 59 |
central nervous | 59 |
viral rnas | 59 |
latent infection | 59 |
virus rna | 59 |
sendai virus | 58 |
endomyocardial biopsy | 58 |
host range | 58 |
wild type | 58 |
respiratory illness | 57 |
mutant spectra | 57 |
electron microscopy | 57 |
initiation factor | 57 |
nucleotide sequence | 57 |
ribosome entry | 57 |
viral quasispecies | 57 |
hela cells | 57 |
nuclear export | 57 |
cell cultures | 57 |
internal ribosome | 57 |
protease inhibitors | 57 |
sars coronavirus | 56 |
zika virus | 56 |
rhinovirus infection | 56 |
genetic material | 56 |
side effects | 56 |
middle east | 55 |
immune evasion | 55 |
human metapneumovirus | 55 |
viral inactivation | 55 |
viral detection | 55 |
cell types | 55 |
viral population | 55 |
cell transmission | 55 |
persistent infection | 54 |
asthma exacerbations | 54 |
copies ml | 54 |
host protein | 54 |
dna polymerase | 54 |
world health | 54 |
generation sequencing | 54 |
entry site | 54 |
even though | 54 |
mutation rate | 54 |
avian influenza | 54 |
east respiratory | 54 |
sense rna | 53 |
recent study | 53 |
high levels | 53 |
pm dm | 53 |
interaction sites | 53 |
health organization | 52 |
molecular mechanisms | 52 |
molecular biology | 52 |
viral particle | 52 |
virus genome | 52 |
viral antigens | 52 |
cellular rna | 51 |
land use | 51 |
mouse model | 51 |
stranded dna | 51 |
different viruses | 51 |
chronic hepatitis | 50 |
interfering rna | 50 |
water samples | 50 |
tract infection | 49 |
i ifn | 49 |
interfering rnas | 49 |
infectious disease | 49 |
animal models | 49 |
host rna | 49 |
wide range | 49 |
tissue culture | 49 |
viral translation | 49 |
encephalitis virus | 48 |
small interfering | 48 |
sialic acid | 48 |
growth factor | 48 |
matrix protein | 48 |
human coronavirus | 48 |
previous studies | 48 |
respiratory specimens | 48 |
genome sequences | 48 |
open reading | 48 |
dilated cardiomyopathy | 47 |
gene therapy | 47 |
structural protein | 47 |
young children | 47 |
dna replication | 47 |
mrna translation | 47 |
acute viral | 47 |
target cell | 47 |
novel viruses | 47 |
receptor binding | 47 |
antiviral response | 46 |
host interactions | 46 |
viral glycoproteins | 46 |
bacterial pathogens | 46 |
disease progression | 46 |
transplant recipients | 46 |
ns protein | 46 |
viral populations | 46 |
monoclonal antibody | 46 |
hospitalized patients | 46 |
influenza vaccine | 45 |
binding sites | 45 |
gene products | 45 |
enteric viruses | 45 |
interaction site | 45 |
rna genomes | 45 |
another study | 45 |
care unit | 45 |
mechanical ventilation | 45 |
cellular immune | 44 |
clinical trial | 44 |
pandemic influenza | 44 |
rabies virus | 44 |
rna silencing | 44 |
cell entry | 44 |
viral titer | 44 |
virus genomes | 44 |
rna sequencing | 44 |
immunocompromised patients | 44 |
left ventricular | 44 |
mice infected | 44 |
leukemia virus | 44 |
antibody response | 44 |
cohort study | 44 |
virus discovery | 44 |
human bocavirus | 43 |
infectious agents | 43 |
cell responses | 43 |
inflammatory cytokines | 43 |
immune cells | 43 |
viral fitness | 43 |
type ii | 43 |
encephalomyocarditis virus | 43 |
also known | 43 |
otitis media | 43 |
frog virus | 43 |
human papillomavirus | 43 |
yellow fever | 43 |
least one | 43 |
severe disease | 42 |
may occur | 42 |
viral vectors | 42 |
crystal structure | 42 |
different viral | 42 |
several studies | 42 |
ribosomal protein | 42 |
viral diversity | 42 |
hospital mortality | 42 |
parainfluenza virus | 42 |
cellular protein | 42 |
closely related | 42 |
high mutation | 42 |
specific ctl | 42 |
bacterial infections | 42 |
caprylic acid | 42 |
viral capsid | 41 |
antiviral immunity | 41 |
envelope proteins | 41 |
viral polymerase | 41 |
plasmid dna | 41 |
viral tubes | 41 |
live attenuated | 41 |
hcv infection | 41 |
host defense | 41 |
deep sequencing | 40 |
viral infectivity | 40 |
rna viral | 40 |
virus strains | 40 |
author funder | 40 |
human cells | 40 |
initiation factors | 40 |
heart disease | 40 |
membrane protein | 40 |
granted medrxiv | 40 |
virus particle | 40 |
cultured cells | 40 |
recent years | 40 |
reading frame | 40 |
metal nanoparticles | 40 |
highly conserved | 40 |
related viruses | 39 |
specific viral | 39 |
gene transfer | 39 |
performed using | 39 |
viral meningitis | 39 |
nucleocapsid protein | 39 |
envelope protein | 39 |
spectrum antiviral | 39 |
several viruses | 39 |
security proteins | 39 |
viral safety | 39 |
polymerase ii | 39 |
secondary bacterial | 39 |
host translation | 39 |
bacterial infection | 39 |
human host | 38 |
quantitative real | 38 |
clinical outcomes | 38 |
mutation rates | 38 |
clinical characteristics | 38 |
dna synthesis | 38 |
fi rst | 38 |
virus assembly | 38 |
untranslated region | 38 |
like receptors | 38 |
pathogenic viruses | 38 |
lymphocytic choriomeningitis | 38 |
lethal mutagenesis | 38 |
viral clearance | 38 |
cell response | 37 |
like receptor | 37 |
spike protein | 37 |
small molecule | 37 |
different types | 37 |
peer review | 37 |
nonstructural protein | 37 |
necrosis factor | 37 |
genome sequence | 37 |
sequence analysis | 37 |
cellular processes | 37 |
previously described | 37 |
reverse genetics | 37 |
antiretroviral therapy | 36 |
protease inhibitor | 36 |
patients infected | 36 |
protein interactions | 36 |
human viruses | 36 |
viral etiology | 36 |
bone marrow | 36 |
fusion protein | 36 |
new viral | 36 |
gene product | 36 |
nuclear pore | 36 |
virus vaccine | 36 |
rna sequences | 36 |
health care | 36 |
two different | 36 |
signaling pathways | 36 |
rna molecules | 36 |
envelope glycoprotein | 36 |
viral myocarditis | 36 |
situ hybridization | 36 |
cell myocarditis | 36 |
like particles | 35 |
escape mutants | 35 |
neutralizing antibody | 35 |
widely used | 35 |
viral spread | 35 |
reading frames | 35 |
low viral | 35 |
severe cap | 35 |
virus evolution | 35 |
viral agents | 35 |
antiviral drug | 35 |
total rna | 35 |
giant cell | 35 |
cl pro | 35 |
binding domain | 35 |
virus production | 35 |
gold nanoparticles | 35 |
vaccine development | 35 |
inflammatory response | 35 |
antiviral effect | 35 |
also found | 35 |
metagenomic analysis | 35 |
one study | 35 |
genetic diversity | 34 |
may lead | 34 |
virus strain | 34 |
host species | 34 |
direct rna | 34 |
disease severity | 34 |
vero cells | 34 |
antigen presentation | 34 |
secondary structure | 34 |
host shutoff | 34 |
cellular dna | 34 |
plasma products | 34 |
cellular membranes | 34 |
mrna degradation | 34 |
hong kong | 34 |
ubiquitin ligase | 34 |
early stage | 34 |
among patients | 34 |
virus ns | 34 |
virus detection | 34 |
bacterial pneumonia | 34 |
quasispecies dynamics | 34 |
epithelial cell | 33 |
type virus | 33 |
dependent manner | 33 |
prolonged viral | 33 |
seasonal influenza | 33 |
cell fusion | 33 |
memory cells | 33 |
hepatitis virus | 33 |
heparan sulfate | 33 |
data suggest | 33 |
infection cycle | 33 |
sequence data | 33 |
systematic review | 33 |
two groups | 33 |
hcv replication | 33 |
viral yield | 33 |
cellular factors | 33 |
takes place | 33 |
cellular mrna | 33 |
viral strains | 33 |
viral communities | 33 |
like protease | 33 |
caspase cleavage | 33 |
higher viral | 32 |
cytopathic effect | 32 |
days post | 32 |
multiplex pcr | 32 |
respiratory distress | 32 |
cell receptor | 32 |
golgi complex | 32 |
post infection | 32 |
plant viruses | 32 |
choriomeningitis virus | 32 |
fatal cases | 32 |
clinical use | 32 |
forest virus | 32 |
determine whether | 32 |
antibody responses | 32 |
virus transmission | 32 |
african swine | 32 |
rhinovirus infections | 32 |
uninfected cells | 31 |
transcription factor | 31 |
cellular rbps | 31 |
transcription factors | 31 |
staphylococcus aureus | 31 |
tobacco mosaic | 31 |
host mrna | 31 |
hbv infection | 31 |
clinical features | 31 |
dna virus | 31 |
population size | 31 |
whole blood | 31 |
semliki forest | 31 |
pure viral | 31 |
low ph | 31 |
viral receptors | 31 |
brain barrier | 31 |
antiviral immune | 31 |
sarcoma virus | 31 |
adhesion molecule | 31 |
antiviral therapies | 31 |
emerging viral | 31 |
hepatocellular carcinoma | 31 |
mass spectrometry | 31 |
acute infection | 31 |
pcr assay | 31 |
new antiviral | 31 |
bacterial co | 31 |
diabetes mellitus | 31 |
coding region | 31 |
nuclear import | 31 |
viral sequence | 31 |
clinical symptoms | 31 |
hcv rna | 31 |
bacterial tracheitis | 30 |
virus isolation | 30 |
viral culture | 30 |
may result | 30 |
dependent translation | 30 |
increased risk | 30 |
total number | 30 |
genetic information | 30 |
infected individuals | 30 |
clinical outcome | 30 |
cell proliferation | 30 |
chikungunya virus | 30 |
clinical samples | 30 |
interferon induction | 30 |
rights reserved | 30 |
sequence space | 30 |
acute myocarditis | 30 |
acid substitutions | 30 |
viral evolution | 30 |
interferon response | 30 |
tumor necrosis | 30 |
signaling pathway | 30 |
throughput sequencing | 30 |
certain viruses | 30 |
site mutants | 30 |
virus spread | 30 |
phase i | 30 |
proteins involved | 30 |
cell receptors | 30 |
complete genome | 30 |
associated herpesvirus | 30 |
rnai screen | 29 |
key role | 29 |
authors declare | 29 |
viral attachment | 29 |
relative abundance | 29 |
antibody titers | 29 |
virus population | 29 |
human rhinoviruses | 29 |
viral sepsis | 29 |
adult patients | 29 |
resistance mutations | 29 |
autoimmune diseases | 29 |
reuse allowed | 29 |
th ctl | 29 |
natural killer | 29 |
translation machinery | 29 |
viral persistence | 29 |
structural basis | 29 |
years old | 29 |
efficient viral | 29 |
pcr assays | 29 |
fusion peptide | 29 |
asthma exacerbation | 29 |
without permission | 29 |
antiviral signaling | 29 |
viral mirnas | 29 |
peripheral blood | 29 |
among children | 29 |
allowed without | 29 |
highly pathogenic | 29 |
viral receptor | 29 |
genomic rnas | 29 |
viruses including | 29 |
inhibit viral | 29 |
chronic viral | 29 |
asthmatic children | 29 |
polysome association | 29 |
antiviral defense | 29 |
molecular weight | 29 |
disease control | 29 |
controlled trial | 29 |
viral community | 28 |
influenza vaccines | 28 |
human respiratory | 28 |
viral diarrhoea | 28 |
classical swine | 28 |
cell membranes | 28 |
studies using | 28 |
commercially available | 28 |
interferon production | 28 |
viral tests | 28 |
ribosomal subunit | 28 |
major histocompatibility | 28 |
human influenza | 28 |
cap structure | 28 |
may contribute | 28 |
respiratory samples | 28 |
see chapter | 28 |
nonenveloped viruses | 28 |
proteasomal degradation | 28 |
gene silencing | 28 |
severe pneumonia | 28 |
host factor | 28 |
envelope glycoproteins | 28 |
common cause | 28 |
zoster virus | 28 |
human plasma | 28 |
conformational changes | 28 |
economic impact | 28 |
eukaryotic cells | 28 |
sequencing technologies | 28 |
phylogenetic analysis | 28 |
viruses use | 28 |
proteolytic cleavage | 28 |
respiratory failure | 28 |
surface proteins | 28 |
sars viral | 28 |
pulmonary disease | 28 |
several viral | 28 |
viral growth | 28 |
virus capsid | 28 |
antiviral effects | 28 |
human pathogens | 28 |
take place | 28 |
viral co | 28 |
replication complex | 28 |
fusion proteins | 28 |
endothelial cells | 28 |
cell type | 28 |
murine leukemia | 28 |
new viruses | 27 |
infected host | 27 |
vigen pipeline | 27 |
cancer patients | 27 |
activated protein | 27 |
virus may | 27 |
clinical presentation | 27 |
core protein | 27 |
defective viral | 27 |
viral components | 27 |
international committee | 27 |
restriction factors | 27 |
viral surface | 27 |
log copies | 27 |
eif gi | 27 |
viral transcripts | 27 |
membrane proteins | 27 |
viral evasion | 27 |
viral antigen | 27 |
molecular basis | 27 |
respiratory symptoms | 27 |
will also | 27 |
bioaerosol sampler | 27 |
ctl response | 27 |
hrv infection | 27 |
norwalk virus | 27 |
rna polymerases | 27 |
persistently infected | 27 |
eukaryotic initiation | 27 |
prospective study | 27 |
virus receptor | 26 |
terminal domain | 26 |
rna structures | 26 |
mrna cap | 26 |
herpes virus | 26 |
infect humans | 26 |
viruses encode | 26 |
respiratory pathogens | 26 |
specific antibodies | 26 |
virus disease | 26 |
viral dynamics | 26 |
mutant virus | 26 |
stem cells | 26 |
replicative fitness | 26 |
rubella virus | 26 |
clinical course | 26 |
may cause | 26 |
antiviral state | 26 |
based purification | 26 |
virus concentration | 26 |
growth rate | 26 |
antiviral agent | 26 |
cervical cancer | 26 |
cellular functions | 26 |
early viral | 26 |
transgenic mice | 26 |
critical role | 26 |
commonly used | 26 |
library preparation | 26 |
copyright holder | 26 |
host response | 26 |
viral reduction | 26 |
enveloped virus | 26 |
hemorrhagic fever | 25 |
viral genetic | 25 |
following infection | 25 |
human disease | 25 |
resistance mechanisms | 25 |
resistant mutants | 25 |
syndrome virus | 25 |
novel antiviral | 25 |
new york | 25 |
cytomegalovirus infection | 25 |
broad spectrum | 25 |
airway epithelial | 25 |
better understanding | 25 |
microbial communities | 25 |
cellular immunity | 25 |
conformational change | 25 |
plaque assay | 25 |
cellular receptors | 25 |
regulate viral | 25 |
viral titers | 25 |
reduced viral | 25 |
lung injury | 25 |
another example | 25 |
host rbps | 25 |
cleavage site | 25 |
early stages | 25 |
cellular receptor | 25 |
sequencing data | 25 |
much less | 25 |
proinflammatory cytokines | 25 |
adverse effects | 25 |
essential role | 25 |
air pollution | 25 |
japanese encephalitis | 25 |
animal virus | 25 |
simian virus | 25 |
active site | 25 |
antigenic variants | 25 |
emerging viruses | 25 |
ctl responses | 25 |
ribosomal proteins | 25 |
vsv infection | 25 |
dendritic cell | 25 |
pcr amplification | 25 |
viral membrane | 25 |
hcv ires | 25 |
specific antibody | 25 |
chronic disease | 25 |
defi ned | 24 |
cellular genes | 24 |
accessory proteins | 24 |
severe respiratory | 24 |
hiv replication | 24 |
room temperature | 24 |
naturally occurring | 24 |
class ii | 24 |
first time | 24 |
virus glycoprotein | 24 |
inducible gtpases | 24 |
rous sarcoma | 24 |
different mechanisms | 24 |
virus metagenomics | 24 |
critically ill | 24 |
treated patients | 24 |
convalescent plasma | 24 |
human health | 24 |
identifi ed | 24 |
viral budding | 24 |
pore complex | 24 |
also reported | 24 |
distress syndrome | 24 |
cytokine production | 24 |
causative agent | 24 |
viral mirna | 24 |
host cellular | 24 |
rna helicase | 24 |
recent advances | 24 |
individual viral | 24 |
remains unclear | 24 |
one patient | 24 |
statistically significant | 24 |
acid sequences | 24 |
well known | 24 |
may help | 24 |
eukaryotic translation | 24 |
clinical practice | 24 |
many viral | 24 |
replicative homeostasis | 23 |
protein expression | 23 |
i ifns | 23 |
viral variants | 23 |
mediated endocytosis | 23 |
error catastrophe | 23 |
emerging infectious | 23 |
disease resistance | 23 |
ifn production | 23 |
short hairpin | 23 |
immune signaling | 23 |
small rnas | 23 |
lymph nodes | 23 |
infection control | 23 |
vast majority | 23 |
like viruses | 23 |
may act | 23 |
following viral | 23 |
neuraminidase inhibitors | 23 |
chronic obstructive | 23 |
coronavirus infection | 23 |
protein levels | 23 |
known viruses | 23 |
antiviral strategies | 23 |
viruses like | 23 |
protein interaction | 23 |
protein complexes | 23 |
protein vp | 23 |
type iii | 23 |
tissue tropism | 23 |
viral structural | 23 |
patients without | 23 |
wide variety | 23 |
entry inhibitors | 23 |
antiviral innate | 23 |
asthma patients | 23 |
viral targets | 23 |
viral mutants | 23 |
genomic dna | 23 |
heat shock | 23 |
mouse hepatitis | 23 |
regulatory factor | 23 |
virion assembly | 23 |
clinical studies | 23 |
ribosome biogenesis | 23 |
gene delivery | 23 |
associated protein | 22 |
beta interferon | 22 |
lipid metabolism | 22 |
full length | 22 |
nonstructural proteins | 22 |
cd cd | 22 |
fatty acid | 22 |
progeny virus | 22 |
genomic sequences | 22 |
previously reported | 22 |
infection period | 22 |
consensus sequence | 22 |
cell contact | 22 |
may represent | 22 |
subcellular localization | 22 |
encoded micrornas | 22 |
picornavirus infections | 22 |
parainfl uenza | 22 |
pattern recognition | 22 |
viral transcription | 22 |
less likely | 22 |
equine encephalitis | 22 |
several different | 22 |
one virus | 22 |
viral fusion | 22 |
influenza hemagglutinin | 22 |
obstructive pulmonary | 22 |
mixed viral | 22 |
alveolar macrophages | 22 |
infectious particles | 22 |
natural history | 22 |
virus life | 22 |
plaque velocity | 22 |
recently reported | 22 |
signal transduction | 22 |
synthetic sirna | 22 |
clinical data | 22 |
fold increase | 22 |
pore size | 22 |
post symptom | 22 |
inhibiting viral | 22 |
viral diagnosis | 22 |
encode proteins | 22 |
virus removal | 22 |
results suggest | 22 |
acute phase | 22 |
induced disease | 22 |
inhibitory effect | 22 |
ifn induction | 22 |
pol fidelity | 22 |
liver cancer | 22 |
protective immunity | 22 |
protein sequences | 22 |
see table | 22 |
viral assembly | 22 |
virus variants | 22 |
virus dna | 22 |
infected animals | 22 |
tumor cells | 22 |
surface receptors | 22 |
respiratory illnesses | 21 |
converting enzyme | 21 |
bronchial epithelial | 21 |
time points | 21 |
innate antiviral | 21 |
standard deviation | 21 |
genetic engineering | 21 |
clinical specimens | 21 |
ifn response | 21 |
gastrointestinal tract | 21 |
acute otitis | 21 |
mrna decay | 21 |
nitric oxide | 21 |
medrxiv preprint | 21 |
potential role | 21 |
virion rna | 21 |
lipid bilayer | 21 |
rna decay | 21 |
endosomal membrane | 21 |
newly synthesized | 21 |
oxidative stress | 21 |
density lipoprotein | 21 |
rna transcripts | 21 |
disease outbreaks | 21 |
cellular machinery | 21 |
animal species | 21 |
clinical disease | 21 |
significantly higher | 21 |
histocompatibility complex | 21 |
gut microbiome | 21 |
viral identification | 21 |
serum antibody | 21 |
positive strand | 21 |
effector cells | 21 |
quality control | 21 |
respiratory diseases | 21 |
direct cell | 21 |
increased susceptibility | 21 |
associated virus | 21 |
initial viral | 21 |
productive infection | 21 |
small molecules | 21 |
affect viral | 21 |
two major | 21 |
subgenomic rna | 21 |
version posted | 21 |
acute asthma | 21 |
host innate | 21 |
severe covid | 21 |
ribosomal entry | 21 |
per year | 21 |
viral families | 21 |
cardiac involvement | 21 |
protein inhibits | 21 |
copy number | 21 |
current knowledge | 21 |
small number | 21 |
myocardial infarction | 21 |
viral metagenomic | 21 |
high frequency | 21 |
neuraminidase inhibitor | 20 |
iav replication | 20 |
persistent infections | 20 |
latently infected | 20 |
golgi stacks | 20 |
viruses also | 20 |
stem cell | 20 |
induced apoptosis | 20 |
among others | 20 |
antiviral properties | 20 |
avian leukosis | 20 |
lymph node | 20 |
severe cases | 20 |
new virus | 20 |
extensively studied | 20 |
cov infection | 20 |
vitro transcription | 20 |
golgi membranes | 20 |
i molecules | 20 |
new host | 20 |
also observed | 20 |
molecular methods | 20 |
viral signal | 20 |
alpha beta | 20 |
clinical manifestations | 20 |
rna modifications | 20 |
cd cells | 20 |
replication machinery | 20 |
quantitative pcr | 20 |
developing countries | 20 |
ribosomal frameshifting | 20 |
cellular pathways | 20 |
large amounts | 20 |
filter media | 20 |
infections may | 20 |
cell interactions | 20 |
web server | 20 |
high level | 20 |
antiviral treatment | 20 |
reference genome | 20 |
inhibitory activity | 20 |
viral pathogen | 20 |
immune recognition | 20 |
million people | 20 |
plasma fractionation | 20 |
lipid droplets | 20 |
factors involved | 20 |
next generation | 20 |
gene regulation | 20 |
whole genome | 20 |
specific cellular | 20 |
replication organelles | 20 |
different stages | 20 |
point mutations | 20 |
short linear | 20 |
copies per | 20 |
membrane structures | 20 |
also used | 20 |
north america | 20 |
dna vaccine | 20 |
vitro studies | 20 |
publicly available | 20 |
rna fragments | 20 |
large dna | 20 |
diagnostic tests | 20 |
emergency department | 20 |
diarrhoea virus | 20 |
viral immune | 20 |
studies suggest | 20 |
internal ribosomal | 20 |
viral host | 20 |
hospital admission | 20 |
various viral | 20 |
crucial role | 20 |
specific th | 20 |
genome sequencing | 20 |
viral ars | 20 |
solid organ | 20 |
genomic material | 19 |
particle size | 19 |
species transmission | 19 |
novel rna | 19 |
bronchoalveolar lavage | 19 |
approved drugs | 19 |
family members | 19 |
host mrnas | 19 |
virus induced | 19 |
feline calicivirus | 19 |
two main | 19 |
age group | 19 |
cells expressing | 19 |
murine model | 19 |
recent report | 19 |
bacterial ars | 19 |
structural units | 19 |
nasal aspirates | 19 |
major role | 19 |
causative agents | 19 |
tract samples | 19 |
targeting viral | 19 |
ill patients | 19 |
short interfering | 19 |
significant differences | 19 |
mononuclear cells | 19 |
protective effect | 19 |
antibody production | 19 |
high sensitivity | 19 |
titer growth | 19 |
host antiviral | 19 |
therapeutic potential | 19 |
cellular rnas | 19 |
hiv aids | 19 |
rna stability | 19 |
sirnas targeting | 19 |
viral transmission | 19 |
normal mice | 19 |
therapeutic agents | 19 |
may provide | 19 |
skeletal muscle | 19 |
infection may | 19 |
one hand | 19 |
thymidine kinase | 19 |
human enterovirus | 19 |
study showed | 19 |
hrv types | 19 |
single amino | 19 |
antiviral compounds | 19 |
iav infections | 19 |
nsp protein | 19 |
translational control | 19 |
kinase activity | 19 |
viral replicase | 19 |
molecular techniques | 19 |
rna template | 19 |
gel electrophoresis | 19 |
healthy adults | 19 |
culture medium | 19 |
cerebrospinal fluid | 19 |
serum samples | 19 |
single nucleotide | 19 |
hek cells | 19 |
humoral immune | 19 |
pediatric patients | 19 |
molecular epidemiology | 19 |
encephalomyelitis virus | 19 |
intracellular parasites | 19 |
complex formation | 19 |
blood cells | 19 |
venezuelan equine | 19 |
sudden death | 19 |
binding activity | 19 |
helicase activity | 19 |
virus inactivation | 19 |
spleen cells | 19 |
sequencing reads | 19 |
also called | 18 |
viral croup | 18 |
ventricular dysfunction | 18 |
proteins may | 18 |
cell protein | 18 |
based assays | 18 |
first step | 18 |
intercellular adhesion | 18 |
healthy individuals | 18 |
clinical applications | 18 |
virus protein | 18 |
virus defective | 18 |
many rna | 18 |
specific antiviral | 18 |
variant viral | 18 |
papilloma virus | 18 |
mutation frequency | 18 |
common viral | 18 |
interferon regulatory | 18 |
cytopathic effects | 18 |
linear motifs | 18 |
age groups | 18 |
cell function | 18 |
proteins required | 18 |
microbial community | 18 |
cytokine storm | 18 |
obligate intracellular | 18 |
viral proteases | 18 |
new insights | 18 |
persistent viral | 18 |
human papilloma | 18 |
one example | 18 |
highly active | 18 |
vrnp complex | 18 |
incubation period | 18 |
acid sequence | 18 |
canine distemper | 18 |
molecular characterization | 18 |
hospitalized children | 18 |
assembly sites | 18 |
purification method | 18 |
positively charged | 18 |
coronavirus replication | 18 |
myocardial involvement | 18 |
cells may | 18 |
nk cells | 18 |
including viral | 18 |
late endosomes | 18 |
acquired immunodeficiency | 18 |
ifn expression | 18 |
proviral dna | 18 |
lipoprotein receptor | 18 |
secondary structures | 18 |
fitness cost | 18 |
delivery systems | 18 |
canine parvovirus | 18 |
virus vaccines | 18 |
messenger rna | 18 |
known viral | 18 |
qtc prolongation | 18 |
antisense rna | 18 |
significant difference | 18 |
major cause | 18 |
relatively low | 18 |
viral isolates | 18 |
novel viral | 18 |
expression levels | 18 |
antiviral responses | 18 |
viral cell | 18 |
evidence suggests | 18 |
immunosuppressive therapy | 18 |
cellular uptake | 18 |
organ transplant | 18 |
virus taxonomy | 18 |
selective translation | 18 |
see also | 18 |
present study | 18 |
high degree | 18 |
cell lysis | 18 |
data collection | 18 |
per cell | 18 |
untranslated regions | 18 |
might also | 18 |
endocytic pathway | 17 |
vacv replication | 17 |
heparan sulphate | 17 |
virus cell | 17 |
linked immunosorbent | 17 |
statistical analysis | 17 |
drug discovery | 17 |
lytic replication | 17 |
infection induces | 17 |
heat treatment | 17 |
specific cd | 17 |
poorly understood | 17 |
immediate early | 17 |
results indicate | 17 |
plant virus | 17 |
sample preparation | 17 |
target viral | 17 |
antiviral efficacy | 17 |
primary infection | 17 |
cellular gene | 17 |
viral ires | 17 |
human lung | 17 |
protein translation | 17 |
bacterial colonization | 17 |
animal model | 17 |
human coronaviruses | 17 |
cell tropism | 17 |
adenovirus type | 17 |
high affinity | 17 |
pseudorabies virus | 17 |
control measures | 17 |
mediated immunity | 17 |
antiviral resistance | 17 |
population dynamics | 17 |
borna disease | 17 |
start codon | 17 |
mutant viruses | 17 |
human infection | 17 |
mg ml | 17 |
low levels | 17 |
kidney cells | 17 |
poliovirus infection | 17 |
virus specific | 17 |
may affect | 17 |
main protease | 17 |
small animal | 17 |
virus nucleoprotein | 17 |
findings suggest | 17 |
human population | 17 |
taken together | 17 |
muscle cells | 17 |
ssrna viruses | 17 |
genome segments | 17 |
recent work | 17 |
virus release | 17 |
presenting cells | 17 |
also shown | 17 |
neuronal cells | 17 |
type infection | 17 |
nucleotide sequences | 17 |
cell biology | 17 |
virus will | 17 |
golgi apparatus | 17 |
also occur | 17 |
polymerase activity | 17 |
dna damage | 17 |
cellular membrane | 17 |
children years | 17 |
currently used | 17 |
informed consent | 17 |
baseline viral | 17 |
hollow fiber | 17 |
logistic regression | 17 |
genome size | 17 |
data set | 17 |
low density | 17 |
mammal species | 17 |
brome mosaic | 17 |
viral hfs | 17 |
host gene | 17 |
potential therapeutic | 17 |
nuclear factor | 17 |
helper virus | 17 |
antigenic diversity | 17 |
ctl activity | 17 |
least two | 17 |
selective pressure | 17 |
virus infected | 17 |
limited number | 17 |
immune escape | 17 |
rapid diagnosis | 17 |
viral enzymes | 17 |
nucleoside analogs | 17 |
pk pd | 17 |
infectious virions | 17 |
also important | 17 |
domestic animals | 17 |
vp vp | 16 |
highly divergent | 16 |
viral copies | 16 |
also identified | 16 |
resistant mutant | 16 |
ventricular arrhythmias | 16 |
study group | 16 |
positive samples | 16 |
human viral | 16 |
neonatal intensive | 16 |
rna degradation | 16 |
sequence alignment | 16 |
swab samples | 16 |
primary cells | 16 |
rift valley | 16 |
many studies | 16 |
recently identified | 16 |
dependent protein | 16 |
exchange chromatography | 16 |
incoming viral | 16 |
cell epitopes | 16 |
time point | 16 |
patients hospitalized | 16 |
many different | 16 |
posterior oropharyngeal | 16 |
ires activity | 16 |
ribonucleic acid | 16 |
virus attachment | 16 |
virus polymerase | 16 |
coat protein | 16 |
hiv rna | 16 |
mek erk | 16 |
translational modification | 16 |
antiviral action | 16 |
chronic hcv | 16 |
proteasome system | 16 |
study also | 16 |
new resistance | 16 |
immune cell | 16 |
differentially expressed | 16 |
molecular mechanism | 16 |
last years | 16 |
synthetic peptides | 16 |
data sets | 16 |
tight junctions | 16 |
viral metagenomes | 16 |
viral discovery | 16 |
viral strategies | 16 |
membrane dynamics | 16 |
molecular detection | 16 |
coding sequences | 16 |
several factors | 16 |
model viruses | 16 |
immunodeficiency syndrome | 16 |
cycle viral | 16 |
cellular environment | 16 |
encoded mirnas | 16 |
viral kinetics | 16 |
vascular endothelial | 16 |
enteroviral infections | 16 |
valley fever | 16 |
dsrna viruses | 16 |
virus species | 16 |
human igg | 16 |
high throughput | 16 |
per sample | 16 |
liver disease | 16 |
binding affinity | 16 |
future studies | 16 |
secretory pathway | 16 |
bvdv isolates | 16 |
respiratory secretions | 16 |
experimental evidence | 16 |
type glycoprotein | 16 |
enhance viral | 16 |
different strains | 16 |
ctl memory | 16 |
will likely | 16 |
nuclear membrane | 16 |
highly sensitive | 16 |
nk cell | 16 |
immunosorbent assay | 16 |
rna structure | 16 |
determined using | 16 |
restriction factor | 16 |
lines represent | 16 |
defense mechanism | 16 |
experimental studies | 16 |
recombination events | 16 |
dna genome | 16 |
coding sequence | 16 |
novel virus | 16 |
rnase iii | 16 |
acid residues | 16 |
parental virus | 16 |
broad range | 16 |
last decade | 16 |
significantly different | 16 |
doublestranded rna | 16 |
samples using | 16 |
free virus | 16 |
block viral | 16 |
lung epithelial | 16 |
infectious bronchitis | 16 |
genetic variability | 16 |
nuclear entry | 16 |
hospital stay | 16 |
defense mechanisms | 16 |
antiviral inhibitors | 16 |
cellular enzymes | 16 |
nuclear localization | 16 |
replication complexes | 16 |
epigenetic repression | 16 |
several mechanisms | 16 |
multiple viruses | 16 |
gold standard | 16 |
recombinant viruses | 16 |
cancer cells | 16 |
infection results | 16 |
diagnostic testing | 16 |
cells via | 16 |
different cell | 16 |
stool samples | 16 |
diatom colony | 16 |
late viral | 16 |
also play | 16 |
children aged | 16 |
healthy children | 16 |
genes involved | 16 |
human rna | 16 |
infl ammatory | 16 |
cell recognition | 16 |
surface expression | 16 |
significantly reduced | 15 |
virus types | 15 |
antibody levels | 15 |
escrt machinery | 15 |
across different | 15 |
disease prevention | 15 |
patients admitted | 15 |
retrospective cohort | 15 |
population level | 15 |
poliovirus rna | 15 |
fatty acids | 15 |
recipient cells | 15 |
genetic variation | 15 |
cell contacts | 15 |
membranotropic peptides | 15 |
large numbers | 15 |
molecule inhibitors | 15 |
lymphocytic myocarditis | 15 |
days later | 15 |
electron microscopic | 15 |
mortality rate | 15 |
hrv infections | 15 |
results showed | 15 |
high risk | 15 |
mechanisms may | 15 |
proteolytic processing | 15 |
human adenovirus | 15 |
experimental rhinovirus | 15 |
confer resistance | 15 |
disease caused | 15 |
cellular components | 15 |
clinical signs | 15 |
rna interactions | 15 |
inflammatory responses | 15 |
rna species | 15 |
cause disease | 15 |
host dna | 15 |
may play | 15 |
genome annotation | 15 |
various viruses | 15 |
like protein | 15 |
viral levels | 15 |
disease pathogenesis | 15 |
will provide | 15 |
many years | 15 |
human airway | 15 |
multiple viral | 15 |
haemophilus influenzae | 15 |
virus isolates | 15 |
diagnostic laboratory | 15 |
polymerase fidelity | 15 |
equine infectious | 15 |
fusion inhibitors | 15 |
human parainfluenza | 15 |
viruses within | 15 |
throat swabs | 15 |
biological relevance | 15 |
lytic infection | 15 |
cell activation | 15 |
potential antiviral | 15 |
negatively charged | 15 |
caspase activation | 15 |
proven myocarditis | 15 |
virus interactions | 15 |
factors associated | 15 |
mathematical models | 15 |
well established | 15 |
increased viral | 15 |
mirna expression | 15 |
induced asthma | 15 |
memory genomes | 15 |
viral gastroenteritis | 15 |
dna vaccines | 15 |
dsdna viruses | 15 |
host defences | 15 |
specific immune | 15 |
reverse transcribed | 15 |
protease activity | 15 |
influenza pandemic | 15 |
flow cytometry | 15 |
virion host | 15 |
viral glycoprotein | 15 |
ex vivo | 15 |
sequence identity | 15 |
mortality rates | 15 |
virus identification | 15 |
genes encoding | 15 |
virus propagation | 15 |
polymerase complex | 15 |
nasopharyngeal swab | 15 |
early steps | 15 |
particular virus | 15 |
viruses replicate | 15 |
sequence reads | 15 |
systemic lupus | 15 |
human diseases | 15 |
drug development | 15 |
two proteins | 15 |
human genome | 15 |
tyrosine kinase | 15 |
long time | 15 |
tissue damage | 15 |
newly discovered | 15 |
load monitoring | 15 |
early gene | 15 |
viral filtration | 15 |
enterovirus infection | 15 |
immune systems | 15 |
therapeutic targets | 15 |
peak viral | 15 |
sewage samples | 15 |
regenerated cellulose | 15 |
lupus erythematosus | 15 |
central role | 15 |
leukosis virus | 15 |
competing interests | 15 |
replication sites | 14 |
infection human | 14 |
interferon system | 14 |
novel human | 14 |
preschool children | 14 |
dependent mechanism | 14 |
mammalian cell | 14 |
rsv infection | 14 |
resistant viruses | 14 |
influenza season | 14 |
viral production | 14 |
regulatory proteins | 14 |
associated reads | 14 |
disease emergence | 14 |
protein interacts | 14 |
observational study | 14 |
different families | 14 |
highly specific | 14 |
negative regulator | 14 |
genetic recombination | 14 |
recognition receptors | 14 |
adaptive immunity | 14 |
new therapeutic | 14 |
integrase inhibitors | 14 |
surface glycoproteins | 14 |
mrna species | 14 |
data indicate | 14 |
efficient replication | 14 |
parainfluenza viruses | 14 |
study using | 14 |
associated coronavirus | 14 |
killer cells | 14 |
bacterial coinfection | 14 |
virus families | 14 |
much higher | 14 |
particle assembly | 14 |
study demonstrated | 14 |
live virus | 14 |
negative control | 14 |
protein sequence | 14 |
replicase complex | 14 |
spiked swabs | 14 |
community acquired | 14 |
associated rna | 14 |
viral transport | 14 |
cell populations | 14 |
past years | 14 |
rna editing | 14 |
multiple studies | 14 |
leader sequence | 14 |
oxygen species | 14 |
also provide | 14 |
antiviral strategy | 14 |
well characterized | 14 |
infecting time | 14 |
serine protease | 14 |
veterinary medicine | 14 |
may serve | 14 |
small rna | 14 |
laboratory diagnosis | 14 |
studies showed | 14 |
gag protein | 14 |
still unknown | 14 |
infectious agent | 14 |
entry inhibitor | 14 |
genetic barrier | 14 |
biopsy specimens | 14 |
viral agent | 14 |
lyme disease | 14 |
signifi cantly | 14 |
per ml | 14 |
progeny virions | 14 |
like virus | 14 |
nasopharyngeal aspirate | 14 |
mammalian virus | 14 |
sample size | 14 |
virological synapse | 14 |
specific virus | 14 |
patients may | 14 |
mammalian viruses | 14 |
oropharyngeal saliva | 14 |
virus matrix | 14 |
data analysis | 14 |
enzyme activity | 14 |
toxic effects | 14 |
odds ratio | 14 |
virus growth | 14 |
saliva samples | 14 |
viruses contain | 14 |
fullerene derivatives | 14 |
promote viral | 14 |
pkr activation | 14 |
sequence homology | 14 |
recombinant virus | 14 |
biological barriers | 14 |
cleavage sites | 14 |
lung tissue | 14 |
viral target | 14 |
national center | 14 |
polymerase inhibitors | 14 |
total cytoplasmic | 14 |
transport medium | 14 |
hiv protease | 14 |
tumor viruses | 14 |
cell growth | 14 |
well defined | 14 |
escherichia coli | 14 |
will allow | 14 |
associated pneumonia | 14 |
also demonstrated | 14 |
significantly increased | 14 |
surface area | 14 |
virus budding | 14 |
surface antigen | 14 |
therapeutic approaches | 14 |
independent mechanism | 14 |
active myocarditis | 14 |
thermo fisher | 14 |
host immunity | 14 |
covalently linked | 14 |
capsid shell | 14 |
frequently used | 14 |
within days | 14 |
drug design | 14 |
virus infectivity | 14 |
virus must | 14 |
inhibitory effects | 14 |
adaptor protein | 14 |
cycle arrest | 14 |
deletion mutants | 14 |
lymphoid cells | 14 |
highly efficient | 14 |
associated molecular | 14 |
rnadependent rna | 14 |
replication cycles | 14 |
clinical relevance | 14 |
may involve | 14 |
disease process | 14 |
defective genomes | 14 |
leading cause | 14 |
viral activity | 14 |
previous study | 14 |
endothelial cell | 14 |
mixed infections | 14 |
attenuated influenza | 14 |
tested positive | 14 |
novel host | 14 |
infect dis | 14 |
without viral | 14 |
significantly lower | 14 |
become infected | 14 |
bronchitis virus | 14 |
cystic fibrosis | 14 |
randomized controlled | 14 |
newcastle disease | 14 |
ub ligases | 14 |
communityacquired pneumonia | 14 |
including hiv | 14 |
stimulated genes | 14 |
early diagnosis | 14 |
membrane vesicles | 14 |
antiretroviral drugs | 14 |
yield assays | 14 |
vaccine candidates | 14 |
weight loss | 14 |
lassa virus | 14 |
independent manner | 14 |
fitness values | 14 |
mumps virus | 14 |
global health | 14 |
virus diversity | 14 |
transformed cells | 14 |
expression level | 14 |
ct values | 14 |
rheumatoid arthritis | 14 |
randomized clinical | 14 |
protein function | 14 |
enzymatic activity | 14 |
time polymerase | 14 |
viral illness | 14 |
silver ions | 13 |
nasal epithelial | 13 |
expression profiles | 13 |
blood mononuclear | 13 |
culture systems | 13 |
latent infections | 13 |
kawasaki disease | 13 |
traditional epidemiological | 13 |
different host | 13 |
rapid spread | 13 |
major capsid | 13 |
virus survival | 13 |
replication fidelity | 13 |
acid amplification | 13 |
inhibit hiv | 13 |
promising results | 13 |
different ways | 13 |
adenovirus infection | 13 |
enclosed within | 13 |
plasmacytoid dendritic | 13 |
hbv replication | 13 |
lung inflammation | 13 |
severe community | 13 |
molecular mimicry | 13 |
pl pro | 13 |
subgenomic rnas | 13 |
macromolecular synthesis | 13 |
virus pathogenesis | 13 |
viruses using | 13 |
antigenic sites | 13 |
etiological agent | 13 |
virus quasispecies | 13 |
surface waters | 13 |
antiviral protein | 13 |
quasispecies memory | 13 |
hiv viral | 13 |
companion animals | 13 |
specific binding | 13 |
virus induces | 13 |
infectious anemia | 13 |
recombinant vaccinia | 13 |
protein kinases | 13 |
therapeutic approach | 13 |
rbd igm | 13 |
organ failure | 13 |
transfected cells | 13 |
per cent | 13 |
social media | 13 |
raf mek | 13 |
magnetic resonance | 13 |
found within | 13 |
fi brosis | 13 |
single virus | 13 |
intravenous immunoglobulin | 13 |
viral capsids | 13 |
induces apoptosis | 13 |
polarized epithelial | 13 |
terminal sequences | 13 |
requiring hospitalization | 13 |
asthma symptoms | 13 |
antibiotic therapy | 13 |
dna encoding | 13 |
additional file | 13 |
surface protein | 13 |
combination therapy | 13 |
risk factor | 13 |
throat swab | 13 |
vaccine virus | 13 |
previously shown | 13 |
cells using | 13 |
mediated translation | 13 |
herpes viruses | 13 |
type viruses | 13 |
hrv type | 13 |
nuclear transport | 13 |
biological functions | 13 |
cell factors | 13 |
viral propagation | 13 |
high concentrations | 13 |
molecular cloning | 13 |
may allow | 13 |
infectious viral | 13 |
binding domains | 13 |
virus mrna | 13 |
containing protein | 13 |
gene transcription | 13 |
many cellular | 13 |
intrinsically disordered | 13 |
intracellular trafficking | 13 |
study reported | 13 |
molecular testing | 13 |
tumor suppressor | 13 |
mrna stability | 13 |
nasopharyngeal swabs | 13 |
fusion peptides | 13 |
viral genotypes | 13 |
single viral | 13 |
sars virus | 13 |
kinase pkr | 13 |
disease onset | 13 |
viral virulence | 13 |
cell adhesion | 13 |
complementary rna | 13 |
rapid viral | 13 |
coxsackie virus | 13 |
initiation codon | 13 |
virus proteins | 13 |
influenza viral | 13 |
several types | 13 |
detect viral | 13 |
another mechanism | 13 |
particles per | 13 |
categorical variables | 13 |
past decade | 13 |
shock protein | 13 |
three main | 13 |
acute lung | 13 |
side chains | 13 |
cdna clones | 13 |
immune complex | 13 |
early studies | 13 |
host genome | 13 |
cdna clone | 13 |
viruses must | 13 |
infl ammation | 13 |
zoonotic viruses | 13 |
clinical significance | 13 |
ribosomal rna | 13 |
confidence interval | 13 |
virus transcription | 13 |
inclusion bodies | 13 |
conserved regions | 13 |
length viral | 13 |
iii ifns | 13 |
validation studies | 13 |
cell population | 13 |
mechanisms involved | 13 |
potential use | 13 |
emerging virus | 13 |
targeted delivery | 13 |
virological synapses | 13 |
severe influenza | 13 |
stress granule | 13 |
inhibits viral | 13 |
mrna levels | 13 |
heart muscle | 13 |
phylogenetic tree | 13 |
mediated antiviral | 13 |
standard virus | 13 |
within hours | 13 |
high proportion | 13 |
entry sites | 13 |
free viral | 13 |
molecular patterns | 13 |
golgi network | 13 |
virus hemagglutinin | 13 |
day post | 13 |
coronavirus nsp | 13 |
viral protease | 13 |
newly infected | 13 |
specific cell | 13 |
cystic fi | 13 |
reactive oxygen | 13 |
chest pain | 13 |
pcr primers | 13 |
reduce viral | 13 |
become available | 13 |
giant cells | 13 |
using viral | 13 |
multivesicular bodies | 13 |
picornavirus infection | 13 |
another virus | 13 |
multiple copies | 13 |
diagnostic tools | 13 |
protein binds | 13 |
nasopharyngeal samples | 13 |
naked dna | 13 |
exact test | 13 |
surveillance system | 13 |
transforming growth | 13 |
method using | 13 |
transgenic plants | 13 |
genetically engineered | 13 |
comparative analysis | 13 |
uenza viruses | 13 |
high fitness | 13 |
occurs via | 13 |
merkel cell | 13 |
homologous recombination | 13 |
complement fixation | 13 |
two types | 13 |
bioinformatics tools | 13 |
ctl epitopes | 13 |
blood samples | 13 |
two decades | 12 |
kinetics parameters | 12 |
based motility | 12 |
refseq records | 12 |
different species | 12 |
fully understood | 12 |
virus host | 12 |
primary human | 12 |
mediated immune | 12 |
ligase complex | 12 |
must also | 12 |
cervical carcinoma | 12 |
immunocompetent adults | 12 |
immune complexes | 12 |
human cell | 12 |
endotracheal intubation | 12 |
transmission dynamics | 12 |
myocarditis associated | 12 |
emerging diseases | 12 |
viral progeny | 12 |
log ml | 12 |
active antiretroviral | 12 |
murine myocarditis | 12 |
case report | 12 |
also present | 12 |
rational design | 12 |
host translational | 12 |
emerging zoonotic | 12 |
protein products | 12 |
two weeks | 12 |
coagulation factors | 12 |
fractionation process | 12 |
point mutation | 12 |
real time | 12 |
cytokine responses | 12 |
virus neuraminidase | 12 |
vaccine design | 12 |
common colds | 12 |
therapeutic options | 12 |
antiviral mechanism | 12 |
initiate translation | 12 |
human body | 12 |
population density | 12 |
red blood | 12 |
aug codon | 12 |
knockout mice | 12 |
cell monolayers | 12 |
surface functionalization | 12 |
nude mice | 12 |
low level | 12 |
coronavirus spike | 12 |
successfully used | 12 |
metagenomic sequencing | 12 |
myocardial damage | 12 |
encoded proteins | 12 |
viral family | 12 |
virus populations | 12 |
often used | 12 |
peptides derived | 12 |
receptor signaling | 12 |
mutations per | 12 |
nuclear envelope | 12 |
decay machinery | 12 |
cell survival | 12 |
clinical application | 12 |
viral cap | 12 |
error threshold | 12 |
ion channel | 12 |
nasopharyngeal aspirates | 12 |
well documented | 12 |
culture cells | 12 |
attachment receptor | 12 |
retrospective study | 12 |
drinking water | 12 |
two distinct | 12 |
rnai screens | 12 |
jc virus | 12 |
well understood | 12 |
like illness | 12 |
experimental infection | 12 |
lesser extent | 12 |
human pathogen | 12 |
posted april | 12 |
new class | 12 |
rna sequence | 12 |
average cellularity | 12 |
target proteins | 12 |
therapeutic intervention | 12 |
will result | 12 |
novel mechanism | 12 |
control group | 12 |
detection methods | 12 |
calculated using | 12 |
virus recovery | 12 |
dna sequences | 12 |
infection due | 12 |
translation elongation | 12 |
facilitate viral | 12 |
murine norovirus | 12 |
biotechnology information | 12 |
three different | 12 |
bunyamwera virus | 12 |
survival rate | 12 |
antiviral activities | 12 |
influenza vaccination | 12 |
proteins vp | 12 |
chronic inflammation | 12 |
pneumoniae infection | 12 |
virus mutant | 12 |
rna pseudoknot | 12 |
resistant influenza | 12 |
polyacrylamide gel | 12 |
acid synthesis | 12 |
rna secondary | 12 |
deficient mice | 12 |
lipid raft | 12 |
pk model | 12 |
allowed us | 12 |
porcine reproductive | 12 |
delivery system | 12 |
distemper virus | 12 |
cell junctions | 12 |
myocyte necrosis | 12 |
drug targets | 12 |
encoded microrna | 12 |
including influenza | 12 |
diagnostic laboratories | 12 |
hypersensitivity myocarditis | 12 |
pcr tests | 12 |
veterinary diagnostic | 12 |
human papillomaviruses | 12 |
ns helicase | 12 |
recent progress | 12 |
given time | 12 |
bovine serum | 12 |
applied biosystems | 12 |
better understand | 12 |
highly structured | 12 |
higher level | 12 |
viral reproduction | 12 |
symptom score | 12 |
vaccine candidate | 12 |
ctl clones | 12 |
prevent viral | 12 |
sequence information | 12 |
type bvdv | 12 |
will focus | 12 |
cell infection | 12 |
high titers | 12 |
rnai machinery | 12 |
idiopathic dilated | 12 |
studies reported | 12 |
virus fitness | 12 |
acidic ph | 12 |
metagenomic approach | 12 |
lung cancer | 12 |
specific igm | 12 |
translation factors | 12 |
saudi arabia | 12 |
mhc molecules | 12 |
viral swarm | 12 |
population structure | 12 |
protein induces | 12 |
significantly associated | 12 |
older age | 12 |
also able | 12 |
virus nonstructural | 12 |
among rna | 12 |
tracheal infections | 12 |
fetal infection | 12 |
two strains | 12 |
hand washing | 12 |
recombinant viral | 12 |
measured using | 12 |
liver cells | 12 |
protein complex | 12 |
apoptotic cell | 12 |
confi rmed | 12 |
viral testing | 12 |
target sequence | 12 |
proteomic analysis | 12 |
viral factors | 12 |
immune function | 12 |
virus molecular | 12 |
bona fide | 12 |
protein response | 12 |
using real | 12 |
immune mechanisms | 12 |
host population | 12 |
infections caused | 12 |
many cases | 12 |
nuclear bodies | 12 |
viruses associated | 12 |
throughput screening | 12 |
respiratory protective | 12 |
viruses detected | 12 |
lipid envelope | 12 |
th century | 12 |
three times | 12 |
enterovirus replication | 12 |
reovirus type | 12 |
cell leukemia | 12 |
efficient translation | 12 |
i interferons | 12 |
based methods | 12 |
virus replicates | 12 |
viral hepatitis | 12 |
diagnostic methods | 12 |
study period | 12 |
virally encoded | 12 |
first line | 12 |
study conducted | 12 |
encoded mirna | 12 |
results show | 12 |
uenza virus | 12 |
lentiviral vector | 12 |
initiate infection | 12 |
significant reduction | 12 |
newly identified | 12 |
mill homogenization | 12 |
human populations | 12 |
major group | 12 |
viral decline | 12 |
viral polymerases | 12 |
igg levels | 12 |
cd ro | 12 |
multivariate analysis | 12 |
several limitations | 12 |
transmembrane proteins | 12 |
leader protein | 12 |
direct interaction | 12 |
coronavirus infections | 12 |
two patients | 12 |
pathogen detection | 12 |
cell surfaces | 12 |
biological replicates | 12 |
described previously | 12 |
cells resulting | 12 |
two viral | 12 |
currently available | 12 |
congestive heart | 12 |
least three | 12 |
unfolded protein | 12 |
terminal region | 12 |
specific viruses | 12 |
effi cacy | 12 |
vitro assembly | 12 |
aasld idsa | 12 |
may require | 12 |
cause severe | 12 |
virus core | 12 |
lymphotropic virus | 12 |
receptor protein | 12 |
long term | 12 |
protein binding | 12 |
methods used | 12 |
error rate | 12 |
diagnostic virology | 12 |
sirna targeting | 12 |
mdck cells | 12 |
molecular diagnosis | 12 |
programmed cell | 12 |
western blot | 12 |
grouper iridovirus | 12 |
cd expression | 12 |
coronary artery | 12 |
also induce | 11 |
cardiovascular disease | 11 |
severe iav | 11 |
based antiviral | 11 |
assay using | 11 |
genome segment | 11 |
naked viruses | 11 |
resistant virus | 11 |
nontreated patients | 11 |
developed countries | 11 |
signifi cant | 11 |
drug repurposing | 11 |
untreated patients | 11 |
viruses enter | 11 |
received oseltamivir | 11 |
reads mapping | 11 |
commonly found | 11 |
conjugating enzyme | 11 |
infectious viruses | 11 |
cellular metabolism | 11 |
protective role | 11 |
plasma protein | 11 |
adults hospitalized | 11 |
also showed | 11 |
previous reports | 11 |
subsequent infection | 11 |
one viral | 11 |
antigenic peptides | 11 |
pneumonia requiring | 11 |
reactive protein | 11 |
inducible gene | 11 |
recent evidence | 11 |
remains unknown | 11 |
positive results | 11 |
statistical significance | 11 |
certain viral | 11 |
receptor molecules | 11 |
secondary concentration | 11 |
successful infection | 11 |
based detection | 11 |
blocking viral | 11 |
particular interest | 11 |
protein involved | 11 |
cell cytosol | 11 |
per genome | 11 |
working group | 11 |
silencing effect | 11 |
authors suggested | 11 |
human endogenous | 11 |
san diego | 11 |
virus inhibition | 11 |
transmissible gastroenteritis | 11 |
vaccination programs | 11 |
disulfide bonds | 11 |
salivary glands | 11 |
predicted proteins | 11 |
childhood asthma | 11 |
bovine respiratory | 11 |
may include | 11 |
cell division | 11 |
virus extinction | 11 |
evolutionarily conserved | 11 |
atypical pneumonia | 11 |
patients presenting | 11 |
potent anti | 11 |
respiratory pathogen | 11 |
qpcr rt | 11 |
viral systems | 11 |
analysis showed | 11 |
wastewater treatment | 11 |
singapore grouper | 11 |
also detected | 11 |
related protein | 11 |
time reverse | 11 |
neighboring cells | 11 |
transplant patients | 11 |
functional analysis | 11 |
common respiratory | 11 |
either directly | 11 |
vaccine efficacy | 11 |
cell carcinoma | 11 |
vascular permeability | 11 |
virus detected | 11 |
potential anti | 11 |
factor eif | 11 |
right ventricular | 11 |
serum albumin | 11 |
electron microscope | 11 |
high prevalence | 11 |
dis doi | 11 |
late genes | 11 |
laboratory testing | 11 |
young adults | 11 |
hepatitis delta | 11 |
lung disease | 11 |
nonhuman primates | 11 |
virus binds | 11 |
drug therapy | 11 |
virus challenge | 11 |
cell memory | 11 |
np swabs | 11 |
viruses identified | 11 |
particularly important | 11 |
rbd igg | 11 |
oral administration | 11 |
later stages | 11 |
host targets | 11 |
seq data | 11 |
rna shedding | 11 |
hbv dna | 11 |
dna sensor | 11 |
lower viral | 11 |
i restricted | 11 |
hairpin rna | 11 |
severe viral | 11 |
well plates | 11 |
complex structure | 11 |
higher concentrations | 11 |
chronic infections | 11 |
virus enters | 11 |
induced tumors | 11 |
multiple mechanisms | 11 |
viral interactions | 11 |
mucosal disease | 11 |
high abundance | 11 |
resistant strains | 11 |
simian immunodeficiency | 11 |
highly virulent | 11 |
viral cdna | 11 |
hcv ns | 11 |
table i | 11 |
human pathogenic | 11 |
hairpin rnas | 11 |
antisense oligonucleotides | 11 |
another group | 11 |
lower limit | 11 |
may vary | 11 |
limit viral | 11 |
role played | 11 |
reference sequence | 11 |
respiratory epithelium | 11 |
antigenic variation | 11 |
cdna synthesis | 11 |
single stranded | 11 |
giant viruses | 11 |
inhibits hiv | 11 |
equine plasma | 11 |
bluetongue virus | 11 |
culture system | 11 |
rhinovirus type | 11 |
modified live | 11 |
nasal secretions | 11 |
sequencing technology | 11 |
virus research | 11 |
see text | 11 |
respiratory system | 11 |
reference sequences | 11 |
small size | 11 |
site mutant | 11 |
rna background | 11 |
time quantitative | 11 |
enter cells | 11 |
viral factories | 11 |
human norovirus | 11 |
control viral | 11 |
large scale | 11 |
mice immunized | 11 |
diagnostic assays | 11 |
specific host | 11 |
eif gii | 11 |
wt strain | 11 |
continuous variables | 11 |
iii ifn | 11 |
interfering virus | 11 |
attachment receptors | 11 |
plasma proteins | 11 |
negative staining | 11 |
wide spectrum | 11 |
rna molecule | 11 |
host genomes | 11 |
conjugation system | 11 |
coated silver | 11 |
innate lymphoid | 11 |
viral resistance | 11 |
infection dynamics | 11 |
animal health | 11 |
chicken eggs | 11 |
bacterial sepsis | 11 |
enhances viral | 11 |
analysis using | 11 |
cell transplant | 11 |
inhibit replication | 11 |
antibodies directed | 11 |
unclear whether | 11 |
host anti | 11 |
systemic infection | 11 |
differential expression | 11 |
factor receptor | 11 |
cell monolayer | 11 |
therapeutic strategies | 11 |
driven translation | 11 |
also cause | 11 |
membrane flux | 11 |
take advantage | 11 |
current status | 11 |
rapid identification | 11 |
viruses viral | 11 |
significant morbidity | 11 |
first described | 11 |
rna segments | 11 |
eukaryotic viruses | 11 |
target sites | 11 |
will continue | 11 |
sense strand | 11 |
cell lysates | 11 |
purified viral | 11 |
negatively regulates | 11 |
vaccine strains | 11 |
higher levels | 11 |
tract disease | 11 |
future research | 11 |
neurotropic viruses | 11 |
replication rate | 11 |
health risks | 11 |
synthetic biology | 11 |
unknown etiology | 11 |
cysteine residues | 11 |
south america | 11 |
mirnas may | 11 |
severe symptoms | 11 |
long terminal | 11 |
rhinovirus colds | 11 |
inhibitors targeting | 11 |
viral inhibition | 11 |
numerous viruses | 11 |
much lower | 11 |
nm ss | 11 |
patients receiving | 11 |
cellular entry | 11 |
york city | 11 |
human herpesvirus | 11 |
atpase activity | 11 |
severe clinical | 11 |
sore throat | 11 |
plaque assays | 11 |
rough endoplasmic | 11 |
increased polysome | 11 |
stimulated gene | 11 |
proteolytic enzymes | 11 |
general population | 11 |
i clinical | 11 |
likely due | 11 |
protein called | 11 |
producing cells | 11 |
evade host | 11 |
mg day | 11 |
mediated gene | 11 |
therapeutic use | 11 |
multiple host | 11 |
natural viral | 11 |
several proteins | 11 |
cellular transcription | 11 |
immune surveillance | 11 |
complete viral | 11 |
hiv type | 11 |
genome amplification | 11 |
template switching | 11 |
light chain | 11 |
epithelial barrier | 11 |
exact mechanism | 11 |
ribosome profiling | 11 |
also serve | 11 |
may prove | 11 |
antigen detection | 11 |
associated proteins | 11 |
virus envelope | 11 |
analyzed using | 11 |